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Abstract: Treatment variation in medicine may be driven by evidence gaps, clinician factors, and
patient preferences. Although well-documented in human medicine, variation in clinical management
is relatively unexplored in veterinary practice. Clinical vignette questionnaires were administered
to a cross section of general practitioners (GPs) and veterinarians with postgraduate training in
ophthalmology (PGs) to survey recommended management of canine prolapsed nictitans gland
(“cherry eye”, PNG) and feline herpesvirus (FHV-1) keratitis. The majority of veterinarians (96.2%)
suggested surgical replacement of cherry eye, with a pocketing technique being the most frequently
nominated procedure. GPs were more likely to suggest gland excision in the event of surgical failure,
while PGs more frequently nominated techniques incorporating a periosteal anchor for salvage
repair. Most respondents managed FHV-1 keratitis with topical antibiotics (76.4%), with a minority
suggesting topical antivirals (32.2%). GPs favoured topical acyclovir whilst PGs more frequently
recommended topical trifluorothymidine. A significantly larger proportion of PGs nominated
systemic famciclovir and lysine supplement for FHV-1 keratitis. This survey revealed moderate
treatment variation for these conditions, both between and within practitioner groups. Additional
research is needed to assess the reasons for this variation, particularly for conditions in which high
quality evidence is scant.
Keywords: cherry eye; nictitans prolapse; third eyelid gland; feline herpes keratitis; treatment
variation; clinical vignette
1. Introduction
Prolapsed nictitans gland (“cherry eye”, PNG) of dogs is a condition commonly encountered by
veterinarians, particularly in predisposed breeds [1,2]. Multiple surgical procedures for correction have
been described in the veterinary literature which require varying surgical proficiency and equipment [3]
(pp. 963–964). Gland excision has been discouraged due to recognition of the gland’s contribution
to tear production and a study showing higher risk of keratoconjunctivitis sicca (KCS) in dogs after
excision [3] (p. 963) [4] (p. 80) [5] (p. 163) [6] (p. 206) [7] . Apart from this fiat, we are unaware of
any directive guidance for management of cherry eye, with surgical technique currently considered a
matter of personal preference [3] (p. 964). Similarly, feline herpesvirus (FHV-1) may result in morbid
and relapsing corneal and conjunctival disease in cats. In contrast to cherry eye, definitive diagnosis of
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FHV-1 keratitis is challenging even with molecular testing [8,9]. No veterinary drugs are labelled for
herpetic keratitis and there is little clinical research to guide treatment decisions in naturally occurring
disease [8,9].
In human medicine, greater treatment variation may occur for conditions which lack high level
evidence or guidelines [10]. Vignette-based questionnaires have been used to assess treatment patterns
and variation in human clinical practice, as well to identify areas of clinical uncertainty [11–13].
Use of open, rather than closed, questions in vignettes may provide better insight into actual current
practice [14]. We are unaware of any published literature documenting treatment patterns of these
two ocular disorders in first opinion or ophthalmology practice. Ophthalmology practice patients may
differ from primary care in a number of ways: cases may vary in severity, as well as available owner
resources and practice capabilities. Heterogeneous management strategies may highlight resource and
evidence gaps encountered by veterinarians in the treatment of these conditions and identify areas of
priority for research in veterinary ophthalmology. The aim of this study was to survey veterinarians
about their management of PNG in dogs and herpetic keratitis in cats. Additionally, we sought to
explore variation in treatment amongst all veterinarians and between veterinarians in general practice
(GPs) and those with additional ophthalmology training (PGs), with reference to published evidence
regarding the treatment of these conditions.
2. Materials and Methods
2.1. Sampling and Data Collection
The target population was all members of the veterinary profession in the UK treating small
animal patients. The sampling frames were a convenience sample of veterinarians on a mailing list for
the Centre for Evidence-based Veterinary Medicine (CEVM) and attendees at the British Association of
Veterinary Ophthalmologists (BrAVO) Winter Conference (2012).
Questionnaires (Supplementary Materials) were constructed consisting of open and closed-end
questions across five sections. These sections covered the diagnostic tools used for ophthalmological
cases, the sources of information accessed by vets, and factors considered in clinical decision-making,
as well as questions relating to respondent demographics. The additional two sections presented
two clinical vignettes—the first based on a Lhasa Apso with a PNG and the second a domestic
shorthaired cat with dendritic herpetic keratitis. After each vignette, veterinarians were asked what
treatments, additional investigations, long term management and recheck advice they would give for
each case. Design of the vignettes was based on “textbook” cases to minimize diagnostic confusion
while the associated questions were derived from a similar survey undertaken [15]. Questionnaires
were pre-tested by eight individuals not engaged in the veterinary profession, and piloted by ten
veterinarians engaged in academic and private practice.
The online questionnaire was constructed and administered through cloud-based survey software
(Survey Monkey Inc., San Mateo, CA, USA) using an email list of interested respondents collected
from a previous survey conducted by the Centre for Evidence-based Veterinary Medicine [16]. Online
respondents were encouraged to fill out the questionnaire by being entered into a prize draw for a
£80 gift voucher in exchange for their participation; respondents were anonymized prior to analysis.
The online survey was initiated in October 2012 and closed in November 2012. A first reminder was
sent 10 days after the initial email, followed by a final reminder two days before survey close. Paper
questionnaires with identical vignette, treatment, diagnostic, and ancillary management questions
were distributed to the attendees of the British Association of Veterinary Ophthalmologists Winter
conference and were collected back by two authors (MB, SB) at the end of the day (3 November 2012).
2.2. Data Management and Analysis
Returned online surveys were downloaded to a spreadsheet (Microsoft Excel) whilst paper survey
responses were manually entered into the same spreadsheet. The data from every 10th questionnaire
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manually entered was checked for any transcription errors. Minimal errors were encountered.
Data relating to proposed treatments and diagnostic investigations were extracted from open ended
responses by one coder (CNW) and categorically classified as to generic drug name or category,
surgical or procedural interventions, diagnostic tests, and other patient assessments. Data related to
long term recommendations were extracted by one coder (CNW) and classified as categorical data
regarding prognosis, salvage treatment options, chronicity, and owner communications. Level of
training in veterinary ophthalmology was assessed by questionnaire and de-anonymized email
addresses after data extraction and coding. Data relating to the sources of information accessed
by vets and factors considered in clinical decision making are not reported here but will appear in an
additional manuscript.
Statistical analysis was performed with a commercially available statistical package (Stata IC13).
Continuous data (age, years since graduation, recheck intervals) were assessed for normality by
the Shapiro–Wilk normality test and were subsequently analyzed by using Mann–Whitney U tests.
Chi-square tests were used to compare categorical data between groups except when expected cell
counts were ≤5, where the more conservative Fisher’s exact test was used. Correction for multiple
comparisons was done using the Dunn–Bonferroni method [17]. Not all respondents answered all
questions; proportions are calculated using the total numbers of respondents completing each question
unless otherwise indicated. Statistical significance was set at the 0.05 level. Significant p values are
reported in text when not included in tables.
Ethical approval for the study was received from the ethics committee at the School of Veterinary
Medicine and Science at the University of Nottingham.
3. Results
3.1. Response Rate
Of 1412 successful email invitations, 269 (18.9%) online surveys were submitted. Of 101 questionnaires
distributed to British Veterinary Ophthalmologist Association (BrAVO) conference attendees, 57 (56.4%)
completed questionnaires were collected. Of the total number of eligible responses received from the
online cohort, 259 were engaged in general practice (from here on known as ”GPs”) while 10 had or
were training for a postgraduate certificate in veterinary ophthalmology. Those 10 were combined
with 50 BrAVO attendees to form a cohort with postgraduate training in veterinary ophthalmology
(from here on known as postgraduate training group, “PGs”). Remaining BrAVO attendees who had
not enrolled in or completed a postgraduate ophthalmology training course (n = 7) were combined
with the GP online cohort. Not all 326 respondents answered all questions within the questionnaire
(Table 1).
Table 1. Demographic and vignette question response rates.
Question Overall n Overall % GP n GP % PG n PG %
Survey 326 266 60
Age 231 70.9 171 64.3 60 100
Gender 231 70.9 171 64.3 60 100
Graduation year 230 70.6 170 63.9 60 100
Initial prolapse treatment 261 80.0 201 75.6 60 100
Prolapse surgical failure treatment 184 56.4 129 48.5 55 91.7
Nictitans additional recommendations 182 55.8 128 48.1 54 90.0
FHV-1 initial treatment 233 71.5 174 65.4 59 98.3
FHV-1 relapse 214 65.6 160 60.2 54 90.0
FHV-1 additional recommendations 233 71.5 174 65.4 59 98.3
3.2. Respondent Characteristics
Fifty eight percent of respondents reporting gender were female. Overall median age of
respondents was 40 years (Table 2). Median age and gender distribution of PGs as compared to GPs was
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not significantly different, although female PGs were marginally more likely to be older than female
GPs. When de-anonymized by email address subsequent to analysis, a majority of PG respondents
were engaged partly (15%) or exclusively (75%) in referral practice. Credentials were verified for
the 60 PG respondents: RCVS Specialist (DVOphthal, DipECVO, FANZCVS, n = 9), Certificate of
Veterinary Ophthalmology (CertVOphthal, n = 38), Post Graduate Certificate in Ophthalmology
(GPCert or PgCert, n = 8), GPCert/PgCert Ophthalmology candidates (n = 2), unnamed certificate in
ophthalmology (n = 1), post-graduate research or training in veterinary ophthalmology (n = 2).
Table 2. Demographic characteristics of GP and PG respondents.
Overall n Overall GP n GP PG n PG p Value
Gender
Male 96 41.6% 66 38.6% 30 50.0% 0.123
Female 135 58.4% 105 61.4% 30 50.0%
No answer given 95 95 0
Age
Median age (all) 230 * 40 171 39 years 59 40 years 0.2151
Median age (male) 94 44 65 45 years 29 42 years 0.5335
Median age (female) 135 36 105 36 years 30 39.5 years 0.0497
No answer age and/or gender 97 96 1
Year of qualification
Median year qualified (all) 230 1996.5 170 1997 60 1995 0.1227
Median year qualified (male) 95 1993 65 1992 30 1994.5 0.9553
Median year qualified (female) 134 1999 104 2000 30 1996.5 0.0541
No answer year and/or gender 97 97 0
* One individual who answered age question provided a range rather than discrete number thus could not be
included in summary data analysis.
3.3. Prolapsed Nictitans Gland
The majority of both groups recommended surgical replacement of a prolapsed gland (Table 3).
PGs were more likely to specify use of a pocket procedure while GPs were less likely to specify type
of surgical procedure. Periosteal anchoring was mentioned by a small number of respondents as
an alternative to pocketing but was rarely recommended as the sole initial technique. A small but
significantly larger proportion of GPs considered gland excision as sole or alternative therapy for the
initial episode of prolapse. A greater proportion of GPs recommended a trial of medical therapy prior
to surgical intervention, although the difference did not reach statistical significance after correction for
multiple comparisons. The most common therapies recommended for medical therapy were topical
steroids (n = 32), manual reduction (n = 24), topical antibiotic (n = 16), and topical lubricant (n = 9).
Table 3. Canine PNG treatments recommended by GP and PG groups responding to a vignette questionnaire.
Treatments Overall n Overall % GP n GP % PG n PG % p Value
Total respondents 261 201 60
All replacement
surgery 251 96.2 191 95.0 60 100 0.078
Pocket 125 47.9 75 37.3 50 83.3 * 0.000
Pocket or anchor 8 3.1 5 2.5 3 5.0 ‡ 0.390
Periosteal anchor 6 2.3 6 3.0 0 0 ‡ 0.342
Unspecified surgery 112 42.9 105 52.2 7 11.7 * 0.000
Excision option 24 9.2 24 11.9 0 0 * 0.005
Excision only 9 3.4 9 4.5 0 0 ‡ 0.124
Medical trial 59 22.6 52 25.9 7 11.7 0.021
* Significant with Bonferroni corrected p < 0.05; bolded p values are significant after correction for multiple
comparison testing; ‡ Fisher’s exact test.
Vet. Sci. 2018, 5, 54 5 of 13
Revision surgery suggestions for surgical failure were more varied and proportions for each
procedure differed from first recommendations (Table 4). GPs were significantly more likely to consider
gland excision than were PGs. PGs more frequently recommended use of periosteal anchoring (either
alone or in combination with pocketing) as compared to their initial treatment suggestions (Figure 1).
Of those who initially chose pocketing, 45% proposed the same technique for revision.
Table 4. Canine PNG surgical failure treatments recommended by GP and PG groups responding to a
vignette questionnaire.
Treatments Overall n Overall % GP n GP % PG n PG % p Value
Total respondents 184 129 55
All replacement surgery 166 90.2 112 86.8 54 98.2 * 0.018
Pocket 51 27.7 31 24.0 20 36.4 0.087
Periosteal anchor 20 10.9 11 8.5 9 16.4 0.118
Pocket or anchor 4 2.2 0 0 4 7.3 *,‡ 0.007
Pocket +/− anchor 5 2.7 0 0 5 9.1 * 0.001
Pocket + anchor 7 3.8 2 1.6 5 9.1 0.014
All techniques with anchoring 36 19.6 13 10.1 23 41.8 * 0.000
Perilimbal pocket (Prémont) 1 0.5 0 0 1 1.8 ‡ 0.299
Unspecified surgery 78 42.4 68 52.7 10 18.2 * 0.000
Excision option 37 20.1 36 27.9 1 1.8 * 0.000
Excision only 10 5.4 10 7.8 0 0 ‡ 0.034
* Significant with Bonferroni corrected p < 0 05; bolded p values are significant after correction for multiple
comparison testing. ‡ Fisher’s exact test.
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Figure 1. Surgical options nominated for treatment of prolapsed nictitans gland on first occurrence and
for recurrence (P, pocket suggestion; A, anchoring suggestion; E, excision; U, unspecified replacement
surgery suggestion).
A significant number of respondents suggested discussing the possibility of surgical failure with
owners with no difference between groups (Table 5). However, PGs were significantly more likely
to note the risk of prolapse in the contralateral eye and marginally more likely to state they would
discuss possible keratoconjunctivitis sicca (KCS) sequelae in the operated eye.
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Table 5. Additional PNG management recommendations by GP and PG groups responding to a
vignette questionnaire.
Recommendation Overall n Overall % GP n GP % PG n PG % p Value
Total respondents 182 128 54
Discuss risk of prolapse in contralateral eye 69 37.9 40 31.3 29 53.7 * 0.004
Warn owner of surgical failure 58 31.9 44 34.4 14 25.9 0.264
Discuss monitoring for KCS 50 27.5 29 22.7 21 38.9 0.025
Recommend prophylactic surgery
contralateral eye 7 3.8 3 2.3 4 7.4
‡ 0.198
* Significant with Bonferroni corrected p < 0.05. ‡ Fisher’s exact test.
Nearly a quarter (n = 47, 23.4%) of GPs offered referral for initial and/or revision replacement
surgery; of those, 23 indicated that they did not have proficiency in surgical replacement. Six GPs
who had recommended periosteal anchoring for initial or revision surgery specified referral for that
procedure. Four of 20 individuals who indicated unavailable treatments indicated that they had no
ability to refer to a veterinary ophthalmologist.
3.4. FHV-1 Keratitis
When presented with the case of feline dendritic keratitis, the majority of both groups recommended
the use of a topical antibiotic (Table 6). Topical antiviral agents and topical lubricants were
recommended by a third of respondents with no significant difference between groups. There were
few recommendations for topical NSAIDs or autologous serum. A variety of topical antibiotics were
nominated (Figure 2). Fusidic acid was most frequently suggested, followed by chloramphenicol
and tetracyclines, with no significant differences found between groups for any agent. Similarly,
a number of topical antiviral drugs were suggested (Figure 3). A significantly higher proportion of
PGs recommended topical trifluorothymidine than did GPs (chi square p = 0.000).
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Table 6. FHV-1 keratitis topical treatments recommended by GP and PG groups responding to a
vignette questionnaire.
Treatments Overall n Overall % GP n GP % PG n PG % p Value
Total respondents 233 174 59
Antibiotic 178 76.4 137 78.7 41 69.5 0.148
Antiviral 75 32.2 58 33.3 17 28.8 0.521
Lubricant 77 33.0 52 29.9 25 42.4 0.078
NSAID 1 8 3.4 8 4.6 0 0.0 ‡ 0.207
Autologous serum 9 3.9 8 4.6 1 1.7 ‡ 0.455
‡ Fisher’s exact test. 1 nonsteroidal anti-inflammatory.
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Figure 3. Topical antiviral choices for FHV-1 keratitis selected by UK general practitioners and postgraduate
groups who suggested topical antiviral therapy in a questionnaire-based survey (ACY, acyclovir;
GAN, ganciclovir; IDO, idoxuridine; TFT, trifluorothymidine; UN, unspecified; numbers indicate
number of respondents suggesting treatment).
Suggested systemic therapies for FHV-1 keratitis were more varied bet een the two groups.
PGs wer significantly more likely to nominate a systemic antiviral (famciclovir when specified)
and lysin supplement (Table 7). Slightly more han a third of all respondent suggested a systemic
nonst roidal anti-inflammatory (NSAID), often citing analges a, with a smal er number of respondents
recommendi g interfero or systemic antibiotics (amoxicillin-clavulanate n = 7, doxycycline n = 12,
clindamycin n = 1, unspecified n = 9).
Table 7. FHV-1 keratitis systemic therapies recommended by GP and PG groups responding to a
vignette questionnaire.
Treatments Overall n Overall % GP n GP % PG n PG % p Value
Total respondents 233 174 59
NSAID 80 34.3 59 33.9 21 35.6 0.814
Meloxicam 41 17. 3 19.5 7 11.9
Carprofen 1 0.4 1 0.6 0 0
Unspecified 38 16.3 24 13.8 14 23.7
Lysine 75 32.2 46 26.4 29 49.2 * 0.001
Antiviral 68 29.2 30 17.2 38 64.4 * 0.000
Famciclovir 65 27.9 27 15.5 38 64.4
Unspecified 3 1.3 3 1.7 0 0
Interferon 33 14.2 24 13.8 9 15.2 0.781
Antibiotic 29 12.4 23 13.2 6 10.2 0.540
* Significant with Bonferroni corrected p < 0.05.
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Additional recommendations for treatment were varied. More than 5% of respondents recommended
discussing recurrence, environmental stress, and issues of contagion (Figure 4). GPs were more likely
to recommend regular vaccination (chi square p = 0.006) whilst PGs were more likely to discuss stress
avoidance (chi square p = 0.001). Few respondents recommended diagnostic testing for FHV-1; when
specified, polymerase chain reaction (PCR) and/or virus isolation was frequently recommended.
In addition to these top five recommendations, 32 additional suggestions were offered by <5% of
respondents which covered surgery (debridement, keratotomy, third eyelid, and conjunctival flaps),
atropine, FeLV/FIV testing, vaccination of contacts, homeopathy, contact lens, steroids, cyclosporine,
deworming, vitamin E, lecithin, and recommendations to avoid vaccination. All recommendations
aside from the top five were suggested only by the GP group with the single exception of one PG who
suggested deworming.
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Figure 4. Additional recommendations for FHV-1 keratitis as nominated by general practitioners and
postgraduate groups based in the UK in a questionnaire-based survey (Recurrence, discussed likelihood
of r currence; Vaccinat , discussed need for regular vaccination; Stress, discussed stress/environmental
triggers; Swab diagnostics, recommended submissi n of ophthalmic wab for diagnostic testing;
Isolate, discussed contagion to other cats and/or recommended isol tion). Numbers i icate number
of responde ts making suggestion.
Recommendations for relapse did not differ substantially from initial treatment suggestions.
The majo ity of respondents suggested repeati g their initial treatm nt advice (71.3% GPs, 81.5%
PGs). A small number of respondents who had not previously suggested surgery (n = 20), antivir l
therapy (n = 15), lysine supplement (n = 7), interferon (n = 9), or systemic antibiotic therapy (n = 3)
did so for relapsed cases. No new recommendations for topical antibiotics were made, although a few
respondents (n = 3) recommended changing to a different antibiotic. Suggested surgical procedures
were keratectomy, debridement, third eyelid flaps, conjunctival flaps, and enucleation.
A number of respondents indicated there were herpesvirus treatments which were unavailable to
them (25.5% GPs, 16.1% PGs). More than half of these (55.5%) suggested that access to antiviral
drugs was limited; although most respondents did not name specific agents, those cited were
trifluorothymidine (n = 4), famciclovir (n = 3), cidofovir (n = 1), and idoxyuridine (n = 1).
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4. Discussion
There appeared to be variation in treatment recommendations elicited by clinical vignettes of
PNG and FHV-1 keratitis, which could potentially impact on the consistency of care given to animals
affected by these conditions. Prior work has demonstrated treatment variation in cardiac, endocrine,
and ocular diseases of companion animals [15,18–20]. This study provides additional evidence for
such variation: although suggestions for initial treatment of PNG were generally consistent amongst
all veterinarians, approaches to surgical failure varied more between GPs and PGs. Moreover, a wider
range of treatments were suggested for FHV-1 keratitis, with larger discordance between GPs and PGs
in the use of systemic agents.
Most respondents suggested surgical replacement of PNG, although more GPs trialed medical
therapy prior to surgical intervention. Most chose a pocket procedure for initial repair (when
the technique was specified). Although a variety of techniques for gland replacement have been
published [7,21–28], there is limited data for comparative efficacy on surgical and lacrimal outcomes,
particularly for breeds thought to be at higher risk for recurrence or for development of KCS.
Morgan’s pocket technique is considered technically less challenging than some other procedures
and is frequently covered in ophthalmology surgical texts [3–6,29], factors which may have driven
popularity amongst respondents. Our finding that periosteal anchoring was suggested more frequently
by PGs for revision surgery suggests that it may be favored in patients more prone to recurrence, a
view reinforced by some authors [28,30] and a recent study showing decreased recurrence in English
Bulldogs when pocketing was augmented with a periosteal tack [22]. It is noteworthy that some of
the GPs in our survey suggested referral specifically for periosteal anchoring, suggesting less comfort
with the surgical technique in that group.
A significantly greater number of GPs considered gland excision in the case of first surgery failure.
Gland excision, though commonly recommended in the past [31], is currently discouraged due to
published evidence of concomitant reduction of tear production [32–35]. Although a retrospective
study associated excision with subsequent development of KCS [7], a number of respondents who
suggested excision as a treatment option stated that they had never encountered this complication.
KCS risk varies by sex, breed, and age [36–38]. It is likely that excision-related KCS may similarly vary
and that willingness to excise may reflect experience with patient mix that is not fully captured by the
published literature. Alternatively, since prolonged prolapse may also be associated with higher KCS
risk [7], respondents may have suggested excision to serve owner cosmetic and financial preferences,
rather than lacrimal function. Finally, since onset of KCS often occurs years after excision (mean
3.06 years, median 4.5 years [7]), it is possible that clinicians who did not report this complication may
have been biased by shorter follow-up times.
Currently and at the time of this survey, there are no approved veterinary pharmaceutical products
for the treatment of FHV-1 keratitis. Suggested therapeutics have generally been derived from
in vitro efficacy studies, experimental infection, and case series reports [8,39]. Topical antibiotics
(recommended by the majority of all respondents) are used in both human and feline keratitis primarily
for the prevention and treatment of secondary infection [8,9,40,41]. Although the difference did not
reach statistical significance, more PG respondents recommended use of a lubricant. We speculate that
lubricants may have been suggested due to tear film abnormalities documented in cats experimentally
infected with FHV-1 [42], as well as to improve ocular comfort [30].
Although a similar proportion of PGs and GPs recommended a topical antiviral, product choice
was disparate between groups, with a larger proportion of PGs suggesting trifluorothymidine. This
may be due, in part, to limited availability of some topical preparations in the UK; trifluorothymidine
must be obtained through the single national ophthalmic compounding pharmacy in the UK. However,
aside from a controlled trial of cidofovir [43], topical antiviral efficacy has generally been deduced
from in vitro and uncontrolled observational data [39]; perhaps as a consequence, disparate product
recommendations are common in veterinary references [5] (pp. 396–399) [30] (p. 250) [44] (p. 470).
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General practitioners and PGs diverged more dramatically in their systemic FHV-1 therapy
recommendations, notably in the greater popularity of famciclovir and lysine amongst PGs. At the
time of this survey, preliminary experimental safety and efficacy data for famciclovir in feline FHV-1
had been published, along with a small case series [45–47]. However, famciclovir therapy had not
yet been included in contemporary texts or was discouraged due to safety concerns [48] (p. 145) [30]
(p. 72) [44] (p. 470). Lysine recommendations also varied between authors at the time of this survey.
The European Cat Advisory Board included lysine as a recommended antiviral agent in their 2009
guidelines [9] whilst a contemporary evidence-based management guide suggested that lysine was
futile at best and could potentially worsen disease and viral shedding [8]. Two recent systematic
reviews summarizing evidence available at the time of this survey have also suggested no evidence
for lysine in prevention or treatment of FHV-1 or prevention of human herpes simplex labialis [49,50].
However, lysine is still considered potentially beneficial by some veterinary ophthalmologists and
virologists [39,51]. Our survey was not designed to elicit reasons for variation but we speculate that
the lower number of lysine suggestions from GPs might reflect differences in information sources,
evidence appraisal, or product availability between the two groups.
Although stress avoidance and recognition of FHV-1 chronicity emerged as consensus themes
amongst respondents, vaccine recommendations varied by practitioner group. Current vaccine
guidelines vary in suggested FHV-1 vaccine intervals due to non-sterilizing immunity and uncertainty
regarding duration of immunity [9,52]; some suggest that FHV-1 may recrudesce in latent carriers
following modified live FHV-1 vaccination [51,53]. Thus, practitioner recommendations may vary
depending on information source. Finally, we were struck by numerous and varied additional
recommendations for management of FHV-1 keratitis. It has been suggested that treatment
proliferation occurs for chronic disease in which little is known and empirical therapy forms the
basis for practice [54] (p. 63).
Treatment variation in human medicine is greater in areas with larger evidence gaps and for
conditions which lack clinical guidelines [10]. Additionally, physician social networks have been
shown to drive regional variation in prostate cancer and coronary artery disease care in the United
States [55,56]. In veterinary medicine, few high quality clinical trials are available, constraining
information sources to lower levels of evidence [57]. In this environment, information sources, social
networks, and client preferences may drive care more substantially and further work in identifying the
sources of veterinary treatment variation is needed. While guidelines may help reduce heterogeneity in
clinical decision making, they are ideally formulated using best available evidence alongside inclusion
of all stakeholders into the guideline process. Our results, combined with the accompanying survey of
current evidence, suggest that there is need for both guidelines for companion animal ocular disease
and additional research to establish optimal treatment for these conditions. In the low resource setting
of veterinary medicine, electronic medical records could be leveraged to collect multicentre cohort
data, create patient registries, and serve as the basis of pragmatic clinical trials.
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